tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Candel Therapeutics price target lowered to $24 from $25 at Citi
PremiumThe FlyCandel Therapeutics price target lowered to $24 from $25 at Citi
25d ago
Candel Therapeutics Advances Cancer Therapies with Strong Q3
Premium
Company Announcements
Candel Therapeutics Advances Cancer Therapies with Strong Q3
25d ago
Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year
Premium
The Fly
Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year
26d ago
Candel Therapeutics initiated with an Outperform at LifeSci Capital
PremiumThe FlyCandel Therapeutics initiated with an Outperform at LifeSci Capital
2M ago
Candel Therapeutics appoints Pulendran to Candel’s RAB
Premium
The Fly
Candel Therapeutics appoints Pulendran to Candel’s RAB
2M ago
Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
Premium
Ratings
Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
2M ago
Promising Investment: Candel Therapeutics’ CAN-2409 Shows Efficacy in Prostate Cancer with Potential for Broader Applications
PremiumRatingsPromising Investment: Candel Therapeutics’ CAN-2409 Shows Efficacy in Prostate Cancer with Potential for Broader Applications
2M ago
Promising Potential of Candel Therapeutics’ CAN-2409: A Versatile Immunotherapy with Broad Applicability
Premium
Ratings
Promising Potential of Candel Therapeutics’ CAN-2409: A Versatile Immunotherapy with Broad Applicability
2M ago
Candel Therapeutics presents Phase 3 clinical trial of CAN-2409
Premium
The Fly
Candel Therapeutics presents Phase 3 clinical trial of CAN-2409
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100